At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 2 enrolled
Drug / intervention
Gemcitabine +2 moredrug
Likely dose
Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open Label Randomized Phase II Trial of Nivolumab + Cabiralizumab (BMS-986227, FPA008) + Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial)
In Brief
A Phase 2 clinical trial evaluating Gemcitabine, Nivolumab 10 MG/ML Intravenous Solution [OPDIVO], and 1 other intervention for Pancreatic Cancer Stage IV. Completed, enrolled 2 participants across 1 site.
Detailed Summary
The purpose of this study is to see if the combination of nivolumab + cabiralizumab + gemcitabine can give prolonged disease control in patients with advanced pancreatic cancer compared to gemcitabine alone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer Stage IV
CountriesUnited States
CollaboratorsStand Up To Cancer, Lustgarten Foundation
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartOct 2019
Primary CompletionApr 2023
Study CompletionJul 2023
TodayJul 2026
First PostedOct 5, 2018
Enrollment StartOct 31, 2019
Primary CompletionApr 12, 2023
Study CompletionJul 13, 2023
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 7.7 years ago
Interventions
Gemcitabinedrug
1000 mg/m2 IV on days 1, 8, and 15 Q4W
Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]drug
480mg IV on Day 1 Q4W
Cabiralizumabdrug
4mg/kg IV on day 1 and 15 Q4W